Feasibility of newborn screening for guanidinoacetate methyltransferase (GAMT) deficiency
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Guanidinoacetate methyltransferase (GAMT) deficiency causes brain creatine deficiency characterized by developmental delays, speech delay, seizures and autism‐like behavior. Identification and therapy at birth because of a positive family history has prevented intellectual disability and seizures in all cases reported. The objective of this study was to develop a method to identify patients with GAMT deficiency from newborn screening blood spots. Creatine and guanidinoacetate were extracted from 10,000 deidentified blood spots using the same protocol routinely used for newborn screening and quantified by stable isotope dilution using deuterated creatine and guanidinoacetate as internal standards. Residual dried blood spots from three infants with GAMT deficiency were used to evaluate the sensitivity of the method. A second tier test using UPLC‐MS/MS was performed to analyze samples with a concentration of guanidinoacetate >2.44 μmol/L (99.5th centile of the normal population). Fifty four blood spots required second tier testing in addition to seven blood spots from three patients with GAMT deficiency retrospectively analyzed. With second tier testing, only the samples from GAMT deficiency patients had elevated concentration of guanidinoacetate. Our results show that GAMT deficiency can be identified in newborns using routine extraction methods. The cost of this additional screening is minimal, as it does not require additional instrumentation, procedure, or sample collection. The use of a second tier test can reduce the false positive rate to a minimum. Summary Brain creatine deficiency syndromes cause mental retardation that can be prevented if therapy is initiated early in life. This manuscript reports that infants with GAMT deficiency (one of the brain creatine deficiency syndromes) can be identified from elevated guanidinoacetate in newborn blood spots with virtually absent false‐positive results using a second tier test.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Newborn screening: toward a uniform screening panel and system—executive summary
Watson, M. S., Mann, M. Y., Lloyd-Puryear, M. A., Rinaldo, P., Howell, R. R., & American College of Medical Genetics Newborn Screening Expert Group (2006) · Pediatrics · doi:10.1542/peds.2005-2633i · Cited by 494
Stöckler, S., Hanefeld, F., & Frahm, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04116-5 · Cited by 240
Cerebral creatine deficiency syndromes: Clinical aspects, treatment and pathophysiology
Stockler, S., Schutz, P. W., & Salomons, G. S. (2007) · Subcellular Biochemistry · doi:10.1007/978-1-4020-6486-9_8 · Cited by 180
Disorders of creatine transport and metabolism
Longo, N., Ardon, O., Vanzo, R., Schwartz, E., & Pasquali, M. (2011) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30292 · Cited by 101
Self-citation
Cited by
Current status of newborn screening worldwide: 2015
Therrell, B. L., Padilla, C. D., Loeber, J. G., Kneisser, I., Saadallah, A., Borrajo, G. J. C., & Adams, J. (2015) · Seminars in Perinatology · doi:10.1053/j.semperi.2015.03.002 · Cited by 602
“Research is also ongoing to develop laboratory methods and assess public perceptions for other conditions including Fragile-X,(47,48) spinal muscular atrophy (SMA),(49,50) Wilson’s disease,(51) and guanidinoacetate methyltransferase (GAMT) deficiency.(52) With increasing interest in NBS, and the possibility of extract…”
BackgroundBrosnan, M. E., & Brosnan, J. T. (2016) · Amino Acids · doi:10.1007/s00726-016-2188-1 · Cited by 185
Metadata
- Authors
- Pasquali, M., Schwarz, E., Jensen, M., Yuzyuk, T., DeBiase, I., Randall, H., & Longo, N.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2013-11-26
- Volume
- 37
- Issue
- 2
- Pages
- 231-236
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W1983423521
- Cited by
- 48
- References
- 4
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.